Skip to main content
. 2017 Sep 14;8(61):103182–103206. doi: 10.18632/oncotarget.20892

Figure 9. The efficacy of inhibiting IRISOE TNBC cells secretome, in vivo.

Figure 9

(A) Schematic representative of experiments performed. (B) FACS analysis for CD29 and CD90 (MSC specific biomarkers), and (C) qRT-PCR analysis for CXCL1 mRNA expression in 3° IRISOE tumors developed in Nu/Nu mice treated with vehicle, Anakinra, SB265610, or both. Circulating CCL2 (D) or VEGF (E) levels in PB from naïve Nu/Nu mice or mice bearing 3° IRISOE orthotopic mammary tumor and treated for 4 days with vehicle, Anakinra, SB265610, or both.